The healthcare giant has been investing heavily in its future growth.

April 20 (Reuters) - Pfizer's Chief Strategy and Innovation Officer, Andrew Baum, is transitioning to a new role and will ...

Pfizer (PFE) and Astellas (ALPMF) (ALPMY) announced Monday that the FDA has granted priority review for their marketing application, which seeks U.S. approval for their antibody drug conjugate, Padcev ...

Global drug maker Pfizer (PFE) and biotech firm Amgen (AMGN), each valued at over HK$1T ($153B), are among 22 strategic ...

U.S. Food and Drug Administration "enforcement in the social media space has historically been somewhat limited, but recent ...

Pfizer executive Andrew Baum, a former Citi analyst, has left his role as an executive vice president and chief strategy and ...

The FDA has scolded Pfizer over Facebook ads for the cancer drug Adcetris, accusing the Big Pharma of failing to adequately ...

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...

In an Untitled Letter, regulators said Facebook promotions for Pfizer’s lymphoma therapy overstated its approved use and ...

Before deciding to walk away from the building, Pfizer tried to list nearly half of the 164,000-square-foot campus for ...

Reputation Institute ranked drug companies from worst to best based on perception from the US. Overall, public trust and ...

The news is the latest example of the biotech industry's struggles in the Bay Area.